Skip to main content
Medical information Clinical review pending

Genetic Testing

Breast Cancer BRCA1 BRCA2 Gene Test

Genetic test to identify mutations in the BRCA1 and BRCA2 genes, which are associated with an increased risk of breast and ovarian cancer. Helps inform risk assessment and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (usually collected via venipuncture). Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for this test. Confirm with the laboratory before booking.
Test priceKSh 30,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Breast Cancer BRCA1 BRCA2 Gene Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Personal history of breast or ovarian cancer
  • ✓Family history of breast or ovarian cancer
  • ✓Family history of other BRCA-related cancers (e.g., prostate, pancreatic)
  • ✓Ashkenazi Jewish ancestry
  • ✓Diagnosis of breast cancer at a young age (e.g., under 50)
  • ✓Considering risk-reducing surgery
  • ✓Evaluating treatment options for certain cancers
02

In plain language

What this test helps you understand

Identifies individuals with an increased genetic risk for breast and ovarian cancer, guiding personalized screening, prevention strategies, and treatment decisions.
The Breast Cancer BRCA1 BRCA2 Gene Test is a genetic analysis that looks for changes (mutations) in the BRCA1 and BRCA2 genes. These genes normally help prevent cancer, but certain mutations can increase the risk of developing breast, ovarian, and other cancers.

Understanding your genetic risk is important for proactive health management. This test can provide valuable information for individuals with a personal or family history of certain cancers.

This test specifically detects mutations in the BRCA1 and BRCA2 genes. Identifying these mutations can help individuals and their healthcare providers make informed decisions about screening, prevention, and treatment options.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this test. Confirm with the laboratory before booking.
SampleBlood sample (usually collected via venipuncture). Confirm with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) or other molecular genetic methods are used to analyze the BRCA1 and BRCA2 genes for mutations. Confirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific mutations in the BRCA1 and BRCA2 genes. It does not detect mutations in other genes associated with cancer risk, nor does it guarantee the absence of cancer. A negative result does not eliminate the risk of developing cancer. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

A positive result indicates that a mutation in either the BRCA1 or BRCA2 gene was found. This suggests an increased lifetime risk of developing certain cancers, particularly breast and ovarian cancer. Discuss the implications with your doctor.
A negative result means that no mutations were detected in the BRCA1 and BRCA2 genes within the scope of the test. However, it does not completely rule out a genetic predisposition to cancer, as other genes or factors may be involved.
Individuals with a strong personal or family history of breast, ovarian, or related cancers, or those from specific ethnic groups with higher mutation prevalence, may be candidates. Consult your doctor.
Insurance coverage varies. Contact your insurance provider to understand your specific policy details regarding genetic testing. Confirm with the laboratory before booking.
Your results should be discussed with your healthcare provider or a genetic counsellor. They can help you understand the implications and discuss appropriate next steps, such as enhanced screening or preventative measures.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp